Allogeneic haemopoietic stem cell transplantation in children: what alternative donor should we choose when no matched sibling is available?
Allogeneic haemopoietic stem cell transplantation has provided curative therapy for life-threatening malignant and non-malignant diseases in children for over 40 years. Only 25% of children in whom an allograft is indicated have the ideal option of a human leucocyte antigen-identical sibling donor. Substantial advances in the use of alternative donors (unrelated volunteer donors, haploidentical family donors and unrelated umbilical cord blood donors) now make it possible for almost all children to benefit from this life-saving treatment. Each donor choice is associated with distinct advantages and disadvantages, which have greater or lesser importance in different diseases. We review the current status of alternative donor transplantation for haematological malignancies, primary immunodeficiencies, inherited metabolic disorders and bone marrow failure syndromes and outline the current UK consensus donor selection algorithms for these disease groups.
Hough
Rachael
R
University College Hospital, London, UK. r.hough@ucl.ac.uk
Cooper
Nicola
N
Veys
Paul
P
D001855:Bone Marrow Diseases / Q000628:therapy; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006648:Histocompatibility; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D008661:Metabolism, Inborn Errors / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D014019:Tissue Donors